AstraZeneca's Imfinzi shows positive results for endometrial cancer patients
26th May 2023 07:02
(Sharecast News) - AstraZeneca said results from a Phase III trial showed its Imfinzi treatment in combination with chemotherapy showed a significant improvement in patients with endometrial cancer.
Read moreAstraZeneca reports positive results in latest lung cancer trials
17th May 2023 07:29
(Sharecast News) - AstraZeneca said on Wednesday that its 'FLAURA2' phase three trial had yielded positive high-level results, demonstrating the potential of 'Tagrisso', or osimertinib, combined with chemotherapy in lung cancer patients.
Read moreDirector dealings: AstraZeneca CFO makes $1.5m sale, IHG chair buys in
9th May 2023 14:28
(Sharecast News) - At the top of the list of FTSE 350 director sells on Tuesday was AstraZeneca, whose chief financial officer sold almost $1.5m worth of the company's American depositary shares.
Read moreAstraZeneca's Farxiga heart failure drug gets extended US approval
9th May 2023 07:16
(Sharecast News) - AstraZeneca's Farxiga drug has been approved in the US to reduce the risk of cardiovascular death, hospitalisation for heart failure and urgent heart failure visits in adults, the company said on Tuesday.
Read moreDirector dealings: Genus announces new CEO's compensation, AstraZeneca chair spends £0.23m
2nd May 2023 12:15
(Sharecast News) - Livestock genetics company Genus saw its shares weaken on Tuesday afternoon after it announced the agreed reward arrangements for its incoming CEO, Jorgen Kokke.
Read moreAstraZeneca 'disappointed' with FDA panel vote on prostate drug
2nd May 2023 08:51
(Sharecast News) - AstraZeneca said it was disappointed with a decision by a panel of US Food and Drug Administration advisers to restrict use of its treatment for a type of prostate cancer.
Read moreAstraZeneca beats Q1 estimates
27th Apr 2023 07:27
(Sharecast News) - AstraZeneca posted better-than-expected first quarter results and reiterated its full-year guidance.
Read moreAstraZeneca inks simpler deal for nirsevimab in US
11th Apr 2023 07:51
(Sharecast News) - AstraZeneca, Swedish Orphan Biovitrum (Sobi) and Sanofi have simplified their contractual arrangements for the development and commercialization of nirsevimab in the US, they announced on Tuesday.
Read moreAstraZeneca reports positive analysis from ovarian cancer trial
5th Apr 2023 07:49
(Sharecast News) - AstraZeneca announced positive high-level results from analysis of an ongoing ovarian cancer treatment trial on Wednesday.
Read moreAstraZeneca drug recommended for EU marketing authorisation
3rd Apr 2023 07:49
(Sharecast News) - An AstraZeneca treatment for a rare autoimmune disease has been given a potential green light by the European Union, the drugs giant said on Monday.
Read moreAstraZeneca's Imfinzi trial shows 'significantly improved' event-free survival rates
9th Mar 2023 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Thursday that results from a phase III trial on its resectable non-small cell lung cancer treatment had shown a "significantly improved" event-free survival.
Read moreAstraZeneca, Daiichi's Enhertu hits trial targets
6th Mar 2023 07:14
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has met prespecified targets in a phase 2 trial the companies said on Monday.
Read moreAstraZeneca, KYM sign licensing deal on gastric cancer treatment
23rd Feb 2023 07:39
(Sharecast News) - AstraZeneca and KYM Biosciences have agreed a global exclusive licence agreement for a potential gastric cancer treatment known as CMG901.
Read moreAstraZeneca FY core EPS in line
9th Feb 2023 07:04
(Sharecast News) - Pharma giant AstraZeneca reported full-year earnings in line with expectations and said it expected 2023 core profits to increase by high-single to low-double digits.
Read moreSector movers: Miners and Big Pharma drag
1st Feb 2023 21:33
(Sharecast News) - Miners were again the main drag on the stock market on a mixed day for industrial metals' prices as traders waited on the Federal Reserve's interest rate decision and policy guidance on Wednesday evening.
Read more